Loading...
01/11 11:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: positive revenue growth and pipeline developments are countered by declining margins, increased expenses, and a net loss. The raised revenue guidance is a positive sign, but the lack of clarity on reimbursement pathways and flat SCC volumes temper enthusiasm. The Q&A reveals some analyst concerns, particularly regarding reimbursement and FDA approval impacts. The absence of a market cap limits prediction accuracy, but the overall sentiment leans towards neutral, given the balancing of positive growth prospects against financial pressures and uncertainties.
Revenue Revenue reached $83 million, representing a significant increase compared to the third quarter of 2024. This growth was driven by a 36% increase in total test report volume, highlighting the success of strategic initiatives and operational strength.
DecisionDx-Melanoma Test Reports 10,459 reports were delivered in the quarter, representing a 12% year-over-year increase. This milestone marks the first time the company surpassed 10,000 reports in a single quarter, driven by strong adoption and clinical utility.
DecisionDx-SCC Test Reports 4,186 test reports were delivered in the third quarter of 2025. This volume was achieved without proactive marketing, underscoring the clinical value and growing evidence supporting the test.
TissueCypher Test Reports 10,609 test reports were delivered in the third quarter, representing a 75% year-over-year growth. This milestone indicates increasing recognition of the test's value by clinicians.
Gross Margin Gross margin during the third quarter of 2025 was 74.7%, compared to 79.2% in the third quarter of 2024. The decline was attributed to higher personnel costs, lab supplies, and lab service expenses due to increased test report volumes.
Operating Expenses Total operating expenses, including cost of sales, were $89.8 million in Q3 2025 compared to $80.7 million in Q3 2024. The increase was driven by higher personnel costs, travel expenses, marketing expenses, and IT-related costs.
Net Loss Net loss for Q3 2025 was $0.5 million compared to net income of $2.3 million in Q3 2024. This shift was influenced by increased operating expenses and investments in growth initiatives.
Adjusted EBITDA Adjusted EBITDA for Q3 2025 was $9.2 million compared to $21.6 million in Q3 2024. The decline reflects higher operating expenses despite strong revenue growth.
Net Cash Provided by Operating Activities Net cash provided by operating activities was $22.6 million for Q3 2025, reflecting strong operational performance and cash flow management.
Launch of AdvanceAD-Tx: Castle Biosciences launched AdvanceAD-Tx, a test designed to guide systemic treatment selection for patients with moderate to severe atopic dermatitis. The test evaluates the expression of 487 genes across 12 immune inflammatory and skin-related pathways. It aims to improve patient outcomes by enabling precision medicine in atopic dermatitis management.
Market size for AdvanceAD-Tx: The target patient population for AdvanceAD-Tx in the U.S. is estimated at 13.2 million individuals aged 12 and older with moderate to severe atopic dermatitis, representing a $33 billion total addressable market opportunity.
Revenue growth: Revenue for Q3 2025 reached $83 million, with total test report volume of 26,841, representing a 36% growth compared to Q3 2024. Full-year revenue guidance was raised to $327 million to $335 million.
Test performance: DecisionDx-Melanoma delivered 10,459 reports in Q3 2025, a 12% year-over-year increase. TissueCypher achieved 10,609 test reports, a 75% year-over-year growth.
Reimbursement strategy for AdvanceAD-Tx: Castle Biosciences is pursuing multiple pathways to accelerate patient access to AdvanceAD-Tx, with revenue contribution expected to be immaterial in 2026 as reimbursement is built from ground zero.
Focus on DecisionDx-Melanoma: The company plans to focus its commercial team on DecisionDx-Melanoma while introducing AdvanceAD-Tx in a phased manner throughout 2026.
Reimbursement Challenges: The company is building reimbursement for the new AdvanceAD-Tx test from ground zero, which is expected to result in immaterial revenue contribution in 2026. This creates uncertainty in revenue generation and financial performance.
High Operating Expenses: Operating expenses, including cost of sales, increased to $89.8 million in Q3 2025 from $80.7 million in Q3 2024. This rise is attributed to higher personnel costs, travel, marketing, and lab-related expenses, which could pressure profitability.
Declining Gross Margin: Gross margin decreased to 74.7% in Q3 2025 from 79.2% in Q3 2024, indicating potential challenges in maintaining cost efficiency as the business scales.
Regulatory and Coverage Risks: The company submitted LCD reconsideration requests for its DecisionDx-SCC test, but there is no specified timeline or guarantee of coverage approval, which could impact the test's market adoption and revenue.
Dependence on Key Products: The company’s revenue heavily relies on a few core tests like DecisionDx-Melanoma and DecisionDx-SCC. Any market or operational challenges affecting these products could significantly impact financial performance.
Market Adoption of New Products: The success of the newly launched AdvanceAD-Tx test depends on market adoption and physician acceptance, which, despite positive initial feedback, remains uncertain.
Economic and Inflationary Pressures: Higher personnel costs and inflationary wage adjustments are contributing to increased expenses, which could impact profitability if not offset by revenue growth.
Revenue Guidance: Castle Biosciences raised its total revenue guidance for 2025 to a range of $327 million to $335 million, up from the previously provided range of $310 million to $320 million.
Launch of AdvanceAD-Tx: The company announced the launch of AdvanceAD-Tx, a test designed to guide systemic treatment selection for patients with moderate to severe atopic dermatitis. The test will be clinically launched on a limited access model in November 2025, with phased expansion throughout 2026. Revenue contribution from this test is expected to be immaterial in 2026 as reimbursement is built from ground zero.
Market Opportunity for AdvanceAD-Tx: The target patient population for AdvanceAD-Tx represents an approximately $33 billion total addressable market opportunity in the U.S. alone, based on a 1-year prevalence of 13.2 million individuals aged 12 and older with moderate to severe atopic dermatitis.
DecisionDx-Melanoma Test: The company expects high single-digit volume growth for DecisionDx-Melanoma for the full year 2025 compared to 2024.
Reimbursement Strategy for AdvanceAD-Tx: Castle Biosciences is pursuing multiple pathways to accelerate patient access to AdvanceAD-Tx, recognizing the need to build a new market and evaluate all available options.
The selected topic was not discussed during the call.
The earnings call presents mixed signals: positive revenue growth and pipeline developments are countered by declining margins, increased expenses, and a net loss. The raised revenue guidance is a positive sign, but the lack of clarity on reimbursement pathways and flat SCC volumes temper enthusiasm. The Q&A reveals some analyst concerns, particularly regarding reimbursement and FDA approval impacts. The absence of a market cap limits prediction accuracy, but the overall sentiment leans towards neutral, given the balancing of positive growth prospects against financial pressures and uncertainties.
The earnings call summary and Q&A indicate positive sentiment, driven by raised revenue guidance, strong growth in TissueCypher and DecisionDx-Melanoma tests, and optimistic future cash flow expectations. Despite some uncertainties in FDA submission timelines and reimbursement pathways, the overall outlook is upbeat. The company's strategic initiatives and growth potential in the GI space further bolster confidence. The market is likely to react positively, with stock price expected to rise by 2% to 8% over the next two weeks.
The earnings call presents mixed signals. Financial performance shows increased net loss and higher expenses, which are negative, but improved adjusted EBITDA is positive. The Q&A reveals cautious optimism with consistent growth for TissueCypher and strategic realignments. However, management's vague responses and lack of immediate revenue impact from acquisitions temper the outlook. The guidance for gross margins and revenue growth is moderate, with no major catalysts to significantly sway the stock price in either direction. Given these factors, a neutral stock price movement is expected over the next two weeks.
The company reported a significant increase in revenue and net income, transitioning from a net loss to a profit. Despite a slight decline in quarterly gross margins, full-year margins improved. The Q&A highlighted growth potential and strategic focus on existing and new verticals. While management avoided specifics on some issues, the overall financial performance and optimistic outlook, including a positive adjusted EBITDA forecast, suggest a positive sentiment. However, the lack of specific guidance on some metrics and potential reimbursement issues could temper enthusiasm, resulting in a moderate positive impact.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
